We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Research to Benefit from Development of a Whole-Genome, Cancer-Specific Microarray

By LabMedica International staff writers
Posted on 14 Mar 2013
Print article
An agreement between a British biotech company and an American-based genomic research consortium paves the way for the development of a whole-genome, cancer-specific microarray.

The biotech company Oxford Gene Technology (Oxford, United Kingdom) will design the microarray for the Cancer Cytogenomics Microarray Consortium (New Orleans, LA, USA). The array will incorporate probes for over 500 cancer genes and 130 cancer-associated genomic regions for hematological and solid tumors. The aim is to improve cancer research through the accurate identification of DNA copy number changes, and loss of heterozygosity associated with different cancer types.

Oxford Gene Technology was chosen following the recent development and commercialization of its CytoSure Haematological Cancer +SNP Array, which targets the four common hematological cancers: chronic lymphocytic leukemia, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome.

The CytoSure Haematological Cancer +SNP array combines long oligo array comparative genomic hybridization probes for superior copy number detection with fully research-validated single nucleotide polymorphism (SNP) content for accurate identification of loss of heterozygosity without concurrent changes in gene copy number. The array content has been optimized to target regions known to be important in hematological cancers while providing good backbone coverage. CytoSure Interpret Software, which accompanies all CytoSure arrays, is a powerful, easy-to-use package for the analysis of copy number variation (CNV) and SNP data. Innovative features enable the automation of data analysis workflows, minimizing the need for user intervention and maximizing the consistency and speed of data interpretation.

The Cancer Cytogenomics Microarray Consortium (New Orleans, LA, USA) was formed in August 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who were interested in applying microarray technologies to cancer diagnosis and cancer research. The mission of the consortium is to promote communication and collaboration among cancer cytogenomics laboratories. The specific goals are to (1) establish platform-neutral and cancer specific microarray designs for diagnostic purposes, (2) share cancer microarray data between participating institutions for education purposes, (3) create a public cancer array database, and (4) carry out multicenter cancer genome translational research. Today, the consortium has grown to include more than 300 members from over 150 organizations in the US, Canada, and in other countries.

“The use of microarray technology will substantially improve the facility of cytogenetics research laboratories to identify cancer,” said Dr. M. Anwar Iqbal, president of the Cancer Cytogenomics Microarray Consortium. “The Cancer Cytogenomics Microarray Consortium board appreciates the efforts of companies such as Oxford Gene Technology to making the Cancer Cytogenomics Microarray Consortium cancer array design available to the cytogenetics research community worldwide.”

Related Links:

Oxford Gene Technology
Cancer Cytogenomics Microarray Consortium


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.